- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03132272
Immunoadsorption for Treatment of Alzheimer's Disease (IMAD)
Efficacy of Immunoadsorption for Treatment of Persons With Alzheimer Dementia and Agonistic Autoantibodies Against alpha1A-adrenoceptor (IMAD)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The IMAD trial outlined aims to ascertain whether the positive effects of immunoadsorption (IA) on slowing down dementia progression, shown in a pilot trial, can be replicated in a slightly larger number of subjects and to comprehensively investigate the effects by a combination of brain and vessel imaging along with cognitive tests and further state-of-the-art cardiovascular, cerebrovascular and laboratory examinations. If the trial results underpin the hypothesis that IA effectively counteracts pathophysiological impairments and dementia-related cognitive decline, it may open up a new treatment approach against dementia, namely the reversal or avoidance of further vascular damage by the removal of agonistic autoantibodies (agAAB) in agAAB-positive persons.
The aim of this study is (beside of safety) to demonstrate the stop of the vascular remodeling and cognition decline by immunoadsorption, a therapeutic method which is well established in cardiology and nephrology.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Mecklenburg-Vorpommern
-
Greifswald, Mecklenburg-Vorpommern, Germany, 17475
- University Medicine Greifswald
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 55-85 years of age
- Diagnosis of Alzheimer's disease
- Presence of agAAB against alpha1-adrenoceptor
- Mini mental state examination (MMSE) score between 19 and 26
- Written informed consent given
Exclusion Criteria:
Haemanalysis:
- Presence of autoantibodies against the N-methyl-D-aspartate (NMDA) receptor
- Defective blood coagulation at time of inclusion
- Severe protein deficiency disorders
- manifest Vitamin/Folic acid deficiency (substitution allowed)
- Active infectious disease, or signs of ongoing infection with C-reactive protein (CRP) >10mmol/L
- Impaired renal function (serum creatinine >220 μmol/L)
- Any disease requiring immunosuppressive drugs or therapeutic antibodies
- Non curative treated malignant disease or another life-threatening disease with poor prognosis (survival less than 2 years), except for basal-cell carcinoma
- Unstable angina pectoris, atrioventricular block (AV block) 2./3. degree or symptomatic sick sinus syndrome without implanted pacemaker, history of myocardial infarct, bypass or other revascularization measures, valvular heart defect (≥ 2. Degree)
- Severely reduced left ventricular systolic function (LVEF < 30%) and/or heart failure symptoms according to New York Heart Association (NYHA) class III/IV
- Clinical manifestation of arterial disease, vascular surgery: No Arteria Carotis Interna (ACI) Stenosis > 60%, peripheral artery occlusive disease (PAOD) > IIb, NASCET, no clinical manifest apparent stroke in anamnesis, MRI: no diffusion disorder, no expired territorial stroke
- Endocrine disorder excluding diabetes mellitus
- Severe hepatic damages (CHILD-Score < 4)
- Severe mental disorders (bipolar disorder, schizophrenia, depression) requiring treatment
- Alcohol or drug abuse
- Drug therapy against dementia since less than 3 months
- Psychopharmacological drug therapy since less than 3 months
- Dialysis requirement
- MRI contraindications (e.g. heart pacemaker)
- Legal tutelage
- Previous treatments with IA or immunoglobulin
- Inability to undergo the study procedure (IA on five consecutive days with subsequent Immunoglobulin G (IgG) substitution)
- treatment with angiotensin-converting-enzyme inhibitors (ACE inhibitors) during the IA (angiotensin receptor blockers (AT-blockers) possible)
- Participation in any other clinical/interventional study within less than 30 days prior to screening date
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Immunoadsorption with Globaffin for Alzheimer Dementia
Immunoadsorption with Globaffin
|
Immunoadsorption for treatment of persons with Alzheimer Dementia
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in cerebral blood flow, estimated by Arterial Spin Labeling MRI
Time Frame: Measurement at 4 times over a 12 months period: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA
|
Measurement of cerebral blood flow and evaluation of changes between baseline and condition after intervention over a 12 months period
|
Measurement at 4 times over a 12 months period: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cognition (changes/improvement/impairment)
Time Frame: Measurement at 4 times: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA
|
Measurement by Alzheimer's Disease Assessment Scale (ADAS-cog)
|
Measurement at 4 times: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA
|
Cognition (changes/improvement/impairment)
Time Frame: Measurement at 4 times: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA
|
Measurement by Mini Mental Status Examination-2 (MMSE)
|
Measurement at 4 times: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA
|
Cognition (changes/improvement/impairment)
Time Frame: Measurement at 4 times: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA
|
Measurement by California Verbal Learning Test (CVLT)
|
Measurement at 4 times: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA
|
Cognition (changes/improvement/impairment)
Time Frame: Measurement at 4 times: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA
|
Measurement by Benton Test
|
Measurement at 4 times: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA
|
Vascular effects
Time Frame: Measurement at 4 times: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA
|
Left ventricular ejection fraction (LVEF)
|
Measurement at 4 times: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA
|
Vascular effects
Time Frame: Measurement at 4 times: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA
|
Endothelial function: measurement by Endo-PAT
|
Measurement at 4 times: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA
|
Vascular effects
Time Frame: Measurement at 4 times: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA
|
Arterial stiffness: measurement by Endo-PAT
|
Measurement at 4 times: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA
|
Vascular effects
Time Frame: Measurement at 4 times: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA
|
Arterial stiffness: measurement by Mobil-O-Graph (pulse wave analysis)
|
Measurement at 4 times: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA
|
Vascular effects
Time Frame: Measurement at 4 times: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA
|
Oxygen saturation: transcutaneous oxygen pressure examinations by PRÉCISE 8008, Medicap
|
Measurement at 4 times: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA
|
Renal function
Time Frame: Measurement at 4 times: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA
|
Nephrosonography: position, size and surface of kidneys, echogenicity, presence and assessment of cysts and tumors, calcifications, nephroliths
|
Measurement at 4 times: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA
|
Renal function
Time Frame: Measurement at 4 times: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA
|
Estimated glomerular Filtration rate (eGFR) using Modification of Diet in Renal Disease (MDRD) formula
|
Measurement at 4 times: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA
|
Laboratory parameters in liquor associated with Alzheimer's disease
Time Frame: Measurement at 2 times: before IA (= baseline) and 12 months after IA
|
Measurement of beta-amyloid and tau species concentrations in liquor (optional; only if subjects gave informed consent in lumbar puncture)
|
Measurement at 2 times: before IA (= baseline) and 12 months after IA
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum analytics
Time Frame: 12 months
|
analysis of agonistic autoantibodies against alpha1A adrenoceptor and measurement of different biomarkers, metabolites associated with Alzheimer's disease in blood samples
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marcus Dörr, Prof.Dr.med., University Medicine Greifswald
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201503IMAD
- CIV-16-02-014668 (Other Identifier: EUDAMED-No.)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Dementia
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
Hebrew SeniorLifeRecruitingAging | Alzheimer Dementia | Presenile Alzheimer DementiaUnited States
-
Istanbul University - Cerrahpasa (IUC)Not yet recruitingDementia, Alzheimer Type | Alzheimer's Disease | Alzheimer DementiaTurkey
-
Otsuka Pharmaceutical Development & Commercialization...Otsuka America PharmaceuticalCompleted
-
University of North Carolina, Chapel HillNational Institute on Aging (NIA)CompletedAlzheimer Dementia | Dementia Alzheimers | CaregiverUnited States
-
Cognito Therapeutics, Inc.Active, not recruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Dementia, Alzheimer Type | Dementia Alzheimers | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Dementia, MildUnited States
-
Mayo ClinicYale University; Columbia University; National Institute on Aging (NIA); Brigham... and other collaboratorsCompletedAlzheimer DementiaUnited States
-
Genescient CorporationCompletedAlzheimer Disease | Alzheimer Dementia
-
Kırıkkale UniversityNot yet recruiting
-
The Hong Kong Polytechnic UniversityUnknown
Clinical Trials on Immunoadsorption with Globaffin
-
Fresenius Medical Care Deutschland GmbHAlcedis GmbHRecruiting
-
University Medicine GreifswaldBristol-Myers Squibb; Krupp von Bohlen und Halbach-Foundation, Essen, Germany; ENDI-Foundation, Bad Homburg, GermanyCompletedDilated CardiomyopathyGermany, Serbia, Sweden
-
Medical University of ViennaElisabethinen HospitalTerminatedAntibody-mediated Rejection | Decreased Immunologic ActivityAustria
-
Hannover Medical SchoolRecruitingFatigue | Post-Acute COVID-19 SyndromeGermany
-
Nanjing University School of MedicineCompleted
-
Manchester University NHS Foundation TrustFresenius AGCompletedAutoimmune Membranous NephropathyUnited Kingdom
-
Charite University, Berlin, GermanyRecruitingImmunoadsorption in Patients With Chronic Fatigue Syndrome Including Patients With Post-COVID-19 CFSME/CFS | Post-COVID ME/CFSGermany
-
University Medical Center GroningenFresenius Medical Care North AmericaCompletedAnti-glomerular Basement Membrane GlomerulonephritisNetherlands
-
Albert Christian Ludolph, Prof.CompletedMultiple Sclerosis | Clinically Isolated SyndromeGermany
-
University of LuebeckCompleted